Paul Utz, MD

Paul Utz (PJ), MD is Professor of Medicine at Stanford School of Medicine in the Department of Medicine, Division of Immunology, where he has directed a translational research lab for 24 years. Dr. Utz co-founded several companies including Bayhill Therapeutics, Tolerion, and Yolo Immune, and has decades of experience as a consultant and SAB member for many biotechnology and pharmaceutical companies.

Dr. Utz studies autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, scleroderma, myositis, Sjögren’s disease, type I diabetes, vasculitis, and multiple sclerosis. His lab is recognized for developing bench-to-bedside technologies, including multiplexed diagnostics and therapeutics, for human immune diseases, including protein and peptide arrays, EpiTOF, HIT, lysate arrays and Intel arrays. His lab has actively pursued research on vaccine responses, therapeutic vaccines for autoimmunity, and host-pathogen response in triggering autoimmunity and inflammation. More recently his lab has pivoted to research on COVID-19, vaccines, emerging pathogens, and Long-COVID (PASC). In addition to his primary role as a physician scientist, Dr. Utz is Associate Dean of Medical Student Research and Director of Department of Medicine’s Team Science research program.

Dr. Utz graduated from King’s College in Wilkes-Barre, PA prior to earning his MD degree from Stanford School of Medicine, where he co-discovered the NFAT transcription factor. He completed internal medicine training at Brigham & Women’s Hospital prior to joining the Stanford faculty in 1999.